What medication should be started after discontinuing enalapril for hypertension, including options like an angiotensin‑II receptor blocker (e.g., losartan) or alternatives if an ARB is not tolerated?

Switch to an ARB (Angiotensin Receptor Blocker)

After discontinuing enalapril for hypertension, you should start an ARB such as losartan as the direct replacement, beginning at a low dose and titrating upward based on blood pressure response.

Recommended Approach

First-Line Replacement: ARB Monotherapy

The most straightforward substitution after stopping enalapril is to initiate an ARB 1, 2. This maintains renin-angiotensin system (RAS) blockade while avoiding ACE inhibitor-specific adverse effects like cough or angioedema.

Starting regimen:

• Losartan 25-50 mg once daily (start low, particularly in elderly or volume-depleted patients) 3
• Alternative ARBs include candesartan (starting 4-8 mg daily) or valsartan (starting 40 mg twice daily) 4
• Titrate upward every 2-4 weeks as tolerated to achieve blood pressure targets 5, 1

If ARB is Not Tolerated

If an ARB cannot be used (rare angioedema cross-reactivity, hyperkalemia, or renal dysfunction), the 2020 ISH guidelines provide clear alternative pathways 1:

For non-Black patients:

1. Add a dihydropyridine calcium channel blocker (DHP-CCB) such as amlodipine
2. Then add a thiazide-like diuretic (chlorthalidone or indapamide preferred over hydrochlorothiazide) 6, 2

For Black patients:

• Start with ARB + DHP-CCB combination or DHP-CCB + thiazide-like diuretic 1

Combination Therapy Considerations

The 2024 ESC and 2025 AHA/ACC guidelines emphasize that most patients with confirmed hypertension (BP ≥140/90 mmHg) should receive combination therapy as initial treatment 6, 2. If blood pressure was inadequately controlled on enalapril alone:

• Preferred combination: ARB + DHP-CCB or ARB + thiazide-like diuretic 2
• Single-pill combinations are strongly recommended to improve adherence 2
• Avoid combining ACE inhibitor with ARB (contraindicated) 4, 7, 2

Critical Safety Monitoring

When initiating ARB therapy after stopping enalapril:

Baseline assessment:

• Check renal function (creatinine, eGFR) and serum potassium before starting 4, 7
• Assess blood pressure in both arms; use the higher reading 1

Follow-up monitoring:

• Recheck renal function and potassium within 1 week of starting ARB 4
• Monitor blood pressure every 2-4 weeks until controlled (target within 3 months) 5, 1
• After dose titration, recheck labs at 1 and 4 weeks 4

Contraindications and cautions:

• Do not use ARB if: Taking aliskiren (especially with diabetes), bilateral renal artery stenosis, pregnancy 3
• Exercise caution with: Serum potassium >5.0 mEq/L, renal insufficiency (CrCl <30 mL/min), symptomatic hypotension 8, 7
• Washout period: Allow 36 hours between stopping enalapril and starting an ARNI (sacubitril-valsartan) to avoid angioedema risk 7

Special Populations

Elderly/frail patients (>80 years):

• Consider monotherapy initially rather than combination 1
• Start with lower ARB doses
• Target BP <150/90 mmHg (individualized based on frailty) 1, 9

Renal impairment:

• ARBs can be used with CrCl >30 mL/min with careful monitoring 4
• Start at lower doses and titrate cautiously
• Monitor for hyperkalemia and worsening renal function

Heart failure patients:

• ARBs are appropriate alternatives when ACE inhibitors are not tolerated 8, 4, 7
• However, if patient has HFrEF and tolerates ACE inhibitors, consider switching to ARNI (sacubitril-valsartan) instead for superior mortality benefit 8, 7

Common Pitfalls to Avoid

1. Don't combine ACE inhibitor + ARB – increases risk of hyperkalemia, hypotension, and renal dysfunction without additional benefit 4, 2

2. Don't forget the washout – If considering ARNI instead of ARB, wait 36 hours after stopping enalapril 7

3. Don't ignore potassium – Concomitant use with potassium supplements, salt substitutes, or potassium-sparing diuretics increases hyperkalemia risk 10, 3

4. Don't underdose – Titrate to evidence-based target doses (e.g., losartan 100 mg daily, candesartan 32 mg daily, valsartan 320 mg daily) for maximum cardiovascular protection 4

5. Don't use in pregnancy – ARBs cause fetal harm; counsel women of childbearing age 3

Evidence Quality Note

ARBs have demonstrated equivalent blood pressure lowering efficacy to ACE inhibitors across multiple trials 11, 12, 13, 14, with a significantly lower incidence of cough (the most common reason for ACE inhibitor discontinuation) 13, 15. While angioedema is less common with ARBs than ACE inhibitors, cross-reactivity can occur in some patients, so caution is warranted if angioedema was the reason for stopping enalapril 8, 7, 15.